Cybin Archives

Psychedelics News

Cybin

Industry

12 Jan 2023

Cybin Selects Generalized Anxiety Disorder for DMT Drug CYB-004

Cybin has selected Generalized Anxiety Disorder as the target indication for its proprietary deuterated N, N-dimethyltryptamine DMT program CYB004....

By Microdose NewsDesk

Industry

28 Dec 2022

2022 Review: 3 Trials Pushing Boundaries of Psychedelic Medicine

James Hallifax takes a look at 3 psychedelic Clinical Trials Pushing Boundaries of Psychedelic Medicine in 2022...

By James Hallifax

Industry

21 Dec 2022

2022 End of Year Review: Cybin

The end of the year is a convenient time to look back on the psychedelic medicine space and take stock on the progress of both the industry and individual companies....

By Microdose NewsDesk

Industry

27 Sep 2022

Cybin Buys License to Mindset Pharma’s Psychedelic Compounds

Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

17 Aug 2022

Cybin Granted Schedule I DEA License for CYB003 Phase 1/2a Trial

Cybin and Clinilabs have been granted Schedule I DEA License for CYB003 Phase 1/2a clinical trial...

By Microdose NewsDesk

Finance, Industry

9 Aug 2022

Cybin Announces Financial Results and $35M Equity Program

Cybin has started the week off with several newsworthy stories....

By Microdose NewsDesk

Science

14 Jul 2022

Science Feature: Next-Generation Psychedelics

Next-generation psychedelics are compounds whose structure derives or is built upon classical psychedelics like DMT, LSD and psilocybin — yet changed by inserting modifications to reduce possible adverse effects....

By Elisabetta Fato

Don’t Miss

28 Jun 2022

News You Might Have Missed: June 28th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

27 Jun 2022

Cybin Receives FDA Clearance for Phase 1/2a Trial

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result